Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Company facts
| Company | Johnson & Johnson |
|---|---|
| Symbol | JNJ |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $641.88B (Massive market data, 2026-09-10) |
| Employees | 140,800 |
| Country | United States |
| Website | https://www.jnj.com |
Trading — Johnson & Johnson
| Last price | $265.58 |
|---|---|
| Change | -0.29% |
| Previous close | $266.35 |
| Day range | $265.25 – $270.40 |
| 50-day average | $262.06 |
| 200-day average | $236.17 |
| Average volume | 8,277,428 |
Price basis: 2026-09-11T21:00:33.773776+00:00
Valuation and financial health
| Earnings per share | $8.73 |
|---|---|
| Price / book | 7.55 |
| Price / cash flow | 23.25 |
| Enterprise value / EBITDA | 19.78 |
| Enterprise value / sales | 6.85 |
| Debt / equity | 0.58 |
| Current ratio | 1.09 |
| Dividend yield | 1.97% |
| Free cash flow | $22.23B |
| Cash ratio | 0.37 |
| Enterprise value | $670.49B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-13 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $2.95 |
| Year-ago EPS | $2.80 |
| Analyst estimates | 6 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for JNJ are on the IntelTrends dashboard.